Consequently, ACPA seropositivity can be used at an early stage as an independent risk factor to predict the probability of joint injury and disability in patients with RA, and ACPA may also serve as a promising drug target for inhibiting IL-1β production. The gene discussed is PRTN3; the disease is rheumatoid arthritis.